DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Bydureon (Exenatide) - Published Studies

 
 



Bydureon Related Published Studies

Well-designed clinical trials related to Bydureon (Exenatide)

Efficacy and tolerability of exenatide once weekly versus sitagliptin in patients with type 2 diabetes mellitus: a retrospective analysis of pooled clinical trial data. [2013]

Exenatide and the treatment of patients with Parkinson's disease. [2013]

Effects of HbA1c and weight reduction on blood pressure in patients with type 2 diabetes mellitus treated with exenatide*. [2012]

Investigation of the haemodynamic effects of exenatide in healthy male subjects. [2012]

Safety, tolerability, pharmacokinetics, and pharmacodynamics of exenatide once weekly in Japanese patients with type 2 diabetes. [2009]

Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study. [2008]

Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study. [2008]

The incretin mimetic exenatide as a monotherapy in patients with type 2 diabetes. [2007]

Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials. [2007]

Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. [2007]

Mathematical modeling shows exenatide improved beta-cell function in patients with type 2 diabetes treated with metformin or metformin and a sulfonylurea. [2006]

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. [2005]

Well-designed clinical trials possibly related to Bydureon (Exenatide)

Pharmacokinetic properties and effects of PT302 after repeated oral glucose loading tests in a dose-escalating study. [2014]

Diabetes medications and body weight. [2009]

Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes. [2008]

Other research related to Bydureon (Exenatide)

Evaluation of exenatide versus insulin glargine for the impact on endothelial functions and cardiovascular risk markers. [2014]

Motor and cognitive advantages persist 12 months after exenatide exposure in Parkinson's disease. [2014]

Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study. [2013]

Cardioprotective effects of exenatide in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of exenatide myocardial protection in revascularization study. [2013]

Clinical effects of once-weekly exenatide for the treatment of type 2 diabetes mellitus. [2013]

Addition of exenatide or sitagliptin to insulin in new onset type 1 diabetes: a randomized, open label study. [2013]

Once weekly exenatide: efficacy, tolerability and place in therapy. [2013]

Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study. [2013]

Addition of exenatide twice daily to basal insulin for the treatment of type 2 diabetes: clinical studies and practical approaches to therapy. [2012]

Exenatide once weekly for the treatment of type 2 diabetes mellitus: clinical results in subgroups of patients using different concomitant medications. [2012]

Use of concomitant glucose-lowering therapies and associated treatment results observed in clinical trials of twice-daily exenatide. [2012]

Baseline factors associated with glycemic control and weight loss when exenatide twice daily is added to optimized insulin glargine in patients with type 2 diabetes. [2012]

Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis. [2011]

Sitagliptin or exenatide once weekly for type 2 diabetes: comparison of the clinical trials. [2011]

Other possibly related research studies

Effects of glucagon-like peptide-1 receptor agonists on body weight: a meta-analysis. [2012]

Liraglutide for the treatment of type 2 diabetes. [2011]

Comparison of liraglutide versus other incretin-related anti-hyperglycaemic agents. [2012]

Liraglutide in oral antidiabetic drug combination therapy. [2012]

The design of the liraglutide clinical trial programme. [2012]

Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults. [2012]

Drug treatment of obesity. [2011]

The safety and tolerability of GLP-1 receptor agonists in the treatment of type 2 diabetes: a review. [2011]

Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies. [2014]

The potential risks of pancreatitis and pancreatic cancer with GLP-1-based therapies are far outweighed by the proven and potential (cardiovascular) benefits. [2013]

GLP-1R agonist therapy for diabetes: benefits and potential risks. [2013]

Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme. [2013]

Combination therapies of DPP4 inhibitors and GLP1 analogues with insulin in type 2 diabetic patients: a systematic review. [2013]

Pharmacological management of obesity in pediatric patients. [2015]

Role of glucagon-like peptide-1 analogue versus amylin as an adjuvant therapy in type 1 diabetes in a closed loop setting with ePID algorithm. [2014]

Glucagon-like peptide 1 receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetes. [2014]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017